Senolytics Compared: Fisetin, Dasatinib + Quercetin, and Navitoclax — What the Evidence Shows (2026)
Most longevity interventions feel like shots in the dark: hope the mechanism holds up, hope it translates to humans, hope you survive the side effects. Senolytics are different. They target something real—senescent cells—and we’ve known what they do to aging for decades. But which one should you actually take?
Senescent cells are the walking dead of your biology. They’ve lost the ability to divide, but they refuse to die. Instead, they sit in your tissues—skin, joints, blood vessels, brain—secreting inflammatory compounds that corrode everything around them. A 2013 Mayo Clinic paper showed that clearing senescent cells in mice extended healthspan and reversed symptoms of aging. That got everyone’s attention.
The Three Senolytic Approaches: Mechanisms and Evidence
Approach 1: Flavonoid Senolytics (Fisetin)
Fisetin is a plant flavonoid found in strawberries, apples, and onions. A 2018 Mayo Clinic paper showed a single injection of fisetin in old mice extended median lifespan by 36% and improved multiple healthspan markers including bone density, cardiac function, and metabolic flexibility.
The advantage is obvious: fisetin is available as an OTC supplement. The problem is that almost all the evidence is pre-clinical. We have one small human study showing fisetin supplementation reduced senescent cell burden, but that’s it.
Approach 2: The D+Q Combo (Dasatinib + Quercetin)
In 2015, the Kirkland lab at Mayo published what became the gold standard for senolytic drug discovery: a combination of dasatinib (a tyrosine kinase inhibitor) and quercetin (a flavonoid) selectively induced apoptosis in senescent cells.
This is different from fisetin. Dasatinib is an FDA-approved cancer drug. Quercetin is a flavonoid. Together, they’re synergistic and more potent than either alone.
Approach 3: BCL-2 Inhibitors (Navitoclax/ABT-263)
Navitoclax (ABT-263) is a BCL-2 and BCL-xL inhibitor originally developed as an anti-cancer agent. The animal data is exceptional, but here’s the problem: navitoclax causes platelet toxicity. You’re trading senescent cell clearance for chronic platelet suppression, which creates its own risks.
My Assessment
If you’re starting out with senolytics: Take fisetin. The risk-benefit ratio is outstanding. You’re unlikely to experience adverse effects.
If you’re committed and well-monitored: Consider D+Q. But you need regular blood work and physician oversight.
Do not take navitoclax. Not yet. The risk profile is too steep for the evidence base.
Disclaimer: This article is for informational purposes only and is not medical advice. Consult your physician before starting any supplement regimen.